Canopy Growth Corp. of Smiths Falls, Ont., has an agreement to buy pharmaceutical distributor MedCann, which has placed the Canadian marijuana company’s Tweed-branded cannabis strains in German pharmacies.
“Germany has begun a process of enabling medical access to cannabis and through a policy that recognized Canopy as the first legal supply source from North America,” said Canopy chairman and CEO Bruce Linton in a statement.
“This acquisition establishes a distinct and purely medicinal corporate entity that helps us today but also positions us for domestic medicinal production inside Germany if the regulatory environment shifts.”
(Sponsored)
In a tough economy, investing in community is more important than ever
When finances are tight, it might seem counterintuitive to give back, but supporting our most vulnerable neighbours this holiday season can actually help businesses weather their own challenges. At United
Family-owned Coke Canada Bottling investing to grow in Ottawa-Gatineau
Have you ever wondered where your favourite Coca-Cola products come from? Few people in know that over 300 popular beverages products, like Coca-Cola, Coke Zero, Fuze, Fanta, Monster Energy, A&W
Mr. Linton has previously said that he wants Canopy to “dominate” the global marijuana market.
The German purchase, subject to approvals, will be made with 674,631 Canopy shares (TSX:CGC), which on Monday closed at $11.22 on the Toronto Stock Exchange, up 5.85 per cent.
At that value, the transaction would be worth about $7.57 million upon closing.
Canopy would also pay up to 490,000 shares over two years if certain performance targets are achieved, bringing the total number of shares to be issued to about 1.16 million – one per cent of Canopy’s current common shares.
Canopy Growth currently has a market value of about $1.29 billion, based on Monday’s stock price.
